This promising anti-hypertensive profile has led to the consideration of mTOR inhibitors as a primary therapy for specialized difficult-to-treat populations with hypertension including pulmonary arterial hypertension and primary hyperaldosteronism (138, 139). The gene discussed is MTOR; the disease is hypertensive disorder.